| [1] Kowalewska M, Danska-Bidzinska A, Bakula-Zalewska E, Bidzinski M. Identification of suitable reference genes for gene expression measurement in uterine sarcoma and car-cinosarcoma tumors. Clin Biochem, 2012, 45(4-5): 368-371.
[2] Zieliáski J, Kusy K. Training-induced adaptation in purine metabolism in high-level sprinters vs. Triathletes. J Appl Physiol, 2012, 112(4): 542-551.
[3] Hüttner E, Speit G, Lambere B, Hou SM, Holzapfel B, Tates A. European HPRT Workshop in Collaboration with GUM Gatersleben-Quedlinburg. Mutat Res, 1996, 359(1): 71-76.
[4] Duan J, Nilsson L, Lambert B. Structural and functional analysis of mutations at the human hypoxanthine phos-phoribosyl transferase (HPRT1) locus. Hum Mutat, 2004, 23(6): 599-611.
[5] Eads JC, Scapin G, Xu YM, Grubmeyer C, Sacchettini JC. The crystal structure of Human hypoxanthine- guanine phosphoribosyltransferase with bound GMP. Cell, 1994, 78(2): 325-334.
[6] Keough DT, Brereton IM, de Jersey J, Guddat LW. The crystal structure of free human hypoxanthine-guanine phosphoribosyltransferase reveals extensive conformational plasticity throughout the catalytic cycle. J Mol Biol, 2005, 351(1): 170-181.
[7] Gogia S, Balaram H, Puranik M. Hypoxanthine guanine phosphoribosyltransferase distorts the purine ring of nu-cleotide substrates and perturbs the pKa of bound xan-thosine monophosphate. Biochemistry, 2011, 50(19): 4184-4193.
[8] Boulton-Jones JR, Pritchard K, Mahmoud AA. The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Aliment Pharmacol Ther, 2000, 14(12): 1561-1565.
[9] Dubinsky MC, Vasiliauskas EA, Singh H, Abreu MT, Papadakis KA, Tran T, Martin P, Vierling JM, Geller SA, Targan SR, Poordad FF. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gas-troenterology, 2003, 125(2): 298-303.
[10] Seinen ML, van Asseldonk DP, Mulder CJ, de Boer NK. Dosing 6-thioguanine in inflammatory bowel disease: expert-based guidelines for daily practice. J Gastrointestin Liver Dis, 2010, 19(3): 291-294.
[11] van Asseldonk DP, Jharap B, Kuik DJ, de Boer NK, Westerveld BD, Russel MG, Kubben FJ, van Bodegraven AA, Mulder CJ. Prolonged thioguanine therapy is well tolerated and safe in the treatment of ulcerative colitis. Dig Liver Dis, 2011, 43(2): 110-115.
[12] Bradford K, Shih DQ. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. World J Gastroenterol, 2011, 17(37): 4166-4173.
[13] Jharap B, Seinen ML, de Boer NKH, van Ginkel JR, Linskens RK, Kneppelhout JC, Mulder CJJ, van Bode-graven AA. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis, 2010, 16(9): 1541-1549.
[14] Schmiegelow K, Al-Modhwahi I, Andersen MK, Behrendtz M, Forestier E, Hasle H, Heyman M, KristinssonJ, Nersting J, Nygaard R, Svendsen AL, Vettenranta K, Weinshilboum R. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Blood, 2009, 113(24): 6077-6084.
[15] De Miranda P, Beacham LM 3rd, Creagh TH, Elion GB. The metabolic fate of the methylnitroimidazole moiety of azathioprine in the rat. J Pharmacol Exp Ther, 1973, 187(3): 588-601.
[16] Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol, 1992, 43(4): 329-339.
[17] Gearry RB, Barclay ML, Roberts RL, Harraway J, Zhang M, Pike LS, George PM, Florkowski CM. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice. Int Med J, 2005, 35(10): 580-585.
[18] Deshpande AR, Abreu MT. Optimizing therapy with 6-mercaptopurine and azathioprine: to measure or not to measure? Therap Adv Gastroenterol, 2010, 3(5): 275-279.
|
